A Phase I Study of Cabozantinib (XL184) in Patients with Differentiated Thyroid Cancer

Background: Cabozantinib targets tyrosine kinases including MET, vascular endothelial growth factor (VEGF) receptor 2, and rearranged during transfection (RET). Differentiated thyroid cancer (DTC) is a tumor type that may be sensitive to cabozantinib. Therefore, we evaluated cabozantinib in a cohort...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Cabanillas, Maria E., Brose, Marcia S., Holland, Jaymes, Ferguson, Kimberly C., Sherman, Steven I.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Mary Ann Liebert, Inc. 2014
Konular:
Thyroid Cancer and Nodules
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4195402/
https://ncbi.nlm.nih.gov/pubmed/25102375
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/thy.2014.0125
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller